Latest Ratios: P/E Ratio 3.0x · EV/EBITDA N/A · ROE 37.1%. (2003–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $184M | $121M | $99M | $94M | $469M | $560M | $72M | $58M | $74M | $115M | $91M |
| Enterprise Value | $139M | $76M | $45M | $136M | $430M | $484M | $52M | $55M | $69M | $111M | $87M |
| P/E Ratio → | 2.99 | 1.90 | — | 16.50 | — | — | — | — | — | — | — |
| P/S Ratio | 91.88 | 60.45 | — | 69.93 | 173.56 | 207.28 | 26.44 | 21.44 | 30.08 | 46.88 | 142.00 |
| P/B Ratio | 0.95 | 0.61 | 0.68 | 0.58 | 3.10 | 4.81 | 2.18 | 2.99 | 2.37 | 5.98 | 3.48 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 19.59 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 19.55 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 37.89 | — | 101.70 | 158.92 | 178.90 | 19.35 | 20.21 | 28.04 | 45.26 | 135.90 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | 1.01 | — | 19.13 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | 18.75 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.7% | 0.7% | — | 100.0% | 100.0% | 100.0% | 96.7% | 96.7% | 96.5% | 92.4% | 23.6% |
| Operating Margin | -754.4% | -754.4% | — | -1176.8% | -1502.0% | -896.2% | -433.8% | -541.3% | -552.3% | -438.6% | -1561.6% |
| Net Profit Margin | 3202.5% | 3202.5% | — | 412.3% | -1397.1% | -822.7% | -424.8% | -531.1% | -519.7% | -426.7% | -1710.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 37.1% | 37.1% | -12.4% | 3.5% | -28.2% | -29.8% | -44.0% | -56.8% | -50.6% | -46.1% | -43.0% |
| ROA | 33.2% | 33.2% | -10.2% | 2.9% | -26.1% | -25.8% | -29.0% | -35.0% | -29.6% | -25.7% | -31.7% |
| ROIC | -9.2% | -9.2% | -6.5% | -7.5% | -40.2% | -68.0% | -59.3% | -52.0% | -49.0% | -43.0% | -34.2% |
| ROCE | -8.4% | -8.4% | -8.1% | -9.8% | -29.3% | -30.0% | -33.9% | -40.5% | -35.4% | -29.6% | -31.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.32 | 0.01 | 0.00 | 0.00 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.23 | -0.37 | 0.26 | -0.26 | -0.66 | -0.58 | -0.17 | -0.16 | -0.21 | -0.15 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -0.84 |
| Interest Coverage | — | — | -17.66 | 1.99 | — | -4037.17 | — | — | -2254.50 | -1795.17 | -910.00 |
Net cash position: cash ($46M) exceeds total debt ($825000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.98 | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 | 6.28 | 6.82 | 3.93 | 8.62 |
| Quick Ratio | 6.98 | 6.98 | 25.19 | 3.06 | 27.34 | 14.27 | 8.93 | 6.28 | 6.82 | 3.93 | 8.62 |
| Cash Ratio | 6.60 | 6.60 | 24.97 | 3.05 | 27.10 | 14.09 | 8.80 | 6.08 | 6.69 | 3.90 | 8.57 |
| Asset Turnover | — | 0.01 | — | 0.01 | 0.02 | 0.02 | 0.06 | 0.08 | 0.05 | 0.06 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 846.07 | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 33.4% | 52.6% | — | 6.1% | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 5.1% |
| Buyback Yield | 2.6% | 3.9% | 2.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 2.6% | 3.9% | 2.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $42M | $41M | $41M | $39M | $28M | $21M | $17M | $15M | $13M | $13M |
Includes 30+ ratios · 22 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ORMP stock.
Oramed Pharmaceuticals Inc.'s current P/E ratio is 3.0x. The historical average is 9.2x. This places it at the 50th percentile of its historical range.
Oramed Pharmaceuticals Inc.'s return on equity (ROE) is 37.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -51.1%.
Based on historical data, Oramed Pharmaceuticals Inc. is trading at a P/E of 3.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Oramed Pharmaceuticals Inc. has 0.7% gross margin and -754.4% operating margin.
Key Metrics
Top Statement Risk
Clinical failure and asset volatility
Metrics are mathematically derived from official filings.
Distorted Multiples Mask Operational Reality
As reported in financial statements, Oramed's P/E ratio of 3.11 appears artificially compressed by non-recurring accounting gains, which, when contrasted with the company's lack of a commercial product, suggests that traditional valuation metrics are currently unreliable indicators of the firm's underlying biotechnology research and development value.
The current P/S ratio of 95.56 reflects a market valuation that is entirely decoupled from the company's negligible revenue base. Investors should monitor the forward EV/EBITDA of 585.01, which suggests that the market is pricing in significant future losses rather than growth, confirming that the stock is trading as a distressed asset rather than a high-growth innovator.
Capital Efficiency Remains Structurally Impaired
Based on reported figures, Oramed's ROIC has consistently trended in negative territory, reaching -4.3% in 2025Q1, which underscores the company's inability to generate productive returns on its invested capital following the failure of its lead clinical program and the subsequent pivot toward speculative financial investments.
The volatility in ROE, which swung from -11.8% to 17.5% over the last ten quarters, is primarily driven by non-operational equity revaluations rather than improvements in core business efficiency. This pattern suggests that the company is failing to compound value through its proprietary POD platform, instead relying on external market fluctuations to bolster its reported financial performance.
Liquidity Buffer Masks Operational Burn
According to recent SEC filings, Oramed's current ratio has fluctuated wildly from 3.06 to 41.06, a trend that reflects the company's erratic cash management and reliance on non-operational asset liquidations rather than a stable, self-sustaining liquidity position capable of supporting long-term clinical development efforts.
While the current ratio appears high, the lack of recurring revenue means that this liquidity is essentially a finite runway that is being consumed by administrative and R&D overhead. The absence of inventory dependence simplifies the quick ratio, but it also highlights the company's vulnerability to capital market conditions should the current cash reserves be exhausted.
Misapplication of Traditional Biotech Ratios
As reported in financial statements, the most commonly misapplied metric for Oramed is the P/E ratio, which obscures the company's status as a pre-commercial entity by suggesting profitability where none exists, thereby misleading investors regarding the firm's true operational health and its reliance on non-recurring accounting gains.
Analysts should instead focus on the cash burn rate and the net asset value of the company's liquid holdings, as these provide a more accurate picture of the firm's survival prospects. Relying on earnings-based multiples for a company that lacks a commercial product is fundamentally flawed and fails to account for the high probability of continued capital dilution.